Anthera Pharmaceuticals Inc
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clini… Read more
Anthera Pharmaceuticals Inc (ANTH) - Total Assets
Latest total assets as of March 2018: $8.81 Million USD
Based on the latest financial reports, Anthera Pharmaceuticals Inc (ANTH) holds total assets worth $8.81 Million USD as of March 2018.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Anthera Pharmaceuticals Inc - Total Assets Trend (2007–2017)
This chart illustrates how Anthera Pharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Anthera Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2017)
Anthera Pharmaceuticals Inc's total assets of $8.81 Million consist of 86.9% current assets and 13.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 59.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $482.00K | 13.1% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2007–2017)
This chart illustrates how Anthera Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Anthera Pharmaceuticals Inc's current assets represent 86.9% of total assets in 2017, a decrease from 99.3% in 2007.
- Cash Position: Cash and equivalents constituted 59.8% of total assets in 2017, up from 2.5% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2007.
- Asset Diversification: The largest asset category is property, plant & equipment at 13.1% of total assets.
Anthera Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Anthera Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Anthera Pharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Anthera Pharmaceuticals Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Anthera Pharmaceuticals Inc is currently not profitable relative to its asset base.
Anthera Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.30 | 3.73 | 14.30 |
| Quick Ratio | 3.30 | 3.39 | 14.30 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $6.09 Million | $ 16.75 Million | $ 45.06 Million |
Anthera Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Anthera Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.11 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -84.4% |
| Total Assets | $3.67 Million |
| Market Capitalization | $2.61K USD |
Valuation Analysis
Below Book Valuation: The market values Anthera Pharmaceuticals Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Anthera Pharmaceuticals Inc's assets decreased by 84.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Anthera Pharmaceuticals Inc (2007–2017)
The table below shows the annual total assets of Anthera Pharmaceuticals Inc from 2007 to 2017.
| Year | Total Assets | Change |
|---|---|---|
| 2017-12-31 | $3.67 Million | -84.35% |
| 2016-12-31 | $23.47 Million | -51.23% |
| 2015-12-31 | $48.12 Million | +1278.94% |
| 2014-12-31 | $3.49 Million | -90.67% |
| 2013-12-31 | $37.42 Million | +41.49% |
| 2012-12-31 | $26.45 Million | -61.95% |
| 2011-12-31 | $69.49 Million | +6.48% |
| 2010-12-31 | $65.26 Million | +1008.26% |
| 2009-12-31 | $5.89 Million | -26.70% |
| 2008-12-31 | $8.03 Million | +29.73% |
| 2007-12-31 | $6.19 Million | -- |